Merck And Orion Announce Mutual Exercise Of Option To Convert Opevesostat Co-Commercialization Agreement Into An Exclusive Global License For Merck; Orion Now Eligible For Development Milestones Up To $30M, Regulatory Milestones Up To $625M, And Sales Milestones Up To $975M
Portfolio Pulse from Benzinga Newsdesk
Merck and Orion have agreed to convert their co-commercialization agreement for Opevesostat into an exclusive global license for Merck. Orion is now eligible for up to $30M in development milestones, $625M in regulatory milestones, and $975M in sales milestones.
July 01, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck has secured an exclusive global license for Opevesostat, potentially boosting its pipeline and future revenues. Orion will receive significant milestone payments.
The exclusive global license for Opevesostat could significantly enhance Merck's product pipeline and future revenue streams. The milestone payments to Orion indicate a strong commitment and potential for high returns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100